- Home
- TR vs GERN Comparison
TR vs GERN Comparison
Compare TR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TR
- GERN
- Stock Information
- Founded
- TR 1896
- GERN 1990
- Country
- TR United States
- GERN United States
- Employees
- TR N/A
- GERN N/A
- Industry
- TR Specialty Foods
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- TR Consumer Staples
- GERN Health Care
- Exchange
- TR Nasdaq
- GERN Nasdaq
- Market Cap
- TR 2.3B
- GERN 2.5B
- IPO Year
- TR N/A
- GERN 1996
- Fundamental
- Price
- TR $31.88
- GERN $3.66
- Analyst Decision
- TR
- GERN Strong Buy
- Analyst Count
- TR 0
- GERN 10
- Target Price
- TR N/A
- GERN $6.95
- AVG Volume (30 Days)
- TR 114.4K
- GERN 9.5M
- Earning Date
- TR 10-24-2024
- GERN 11-07-2024
- Dividend Yield
- TR 1.13%
- GERN N/A
- EPS Growth
- TR 7.80
- GERN N/A
- EPS
- TR 1.31
- GERN N/A
- Revenue
- TR $727,121,000.00
- GERN $29,480,000.00
- Revenue This Year
- TR N/A
- GERN $30,930.80
- Revenue Next Year
- TR N/A
- GERN $315.72
- P/E Ratio
- TR $24.28
- GERN N/A
- Revenue Growth
- TR N/A
- GERN 9199.68
- 52 Week Low
- TR $27.58
- GERN $1.64
- 52 Week High
- TR $34.80
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- TR 61.63
- GERN 29.99
- Support Level
- TR $29.17
- GERN $3.98
- Resistance Level
- TR $32.87
- GERN $4.50
- Average True Range (ATR)
- TR 0.59
- GERN 0.21
- MACD
- TR 0.27
- GERN -0.05
- Stochastic Oscillator
- TR 73.24
- GERN 3.45
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.